ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2015
Communication Challenges During the Development and Introduction of a New Meningococcal Vaccine in Africa.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Anxiety-related adverse events following immunization (AEFI): A systematic review of published clusters of illness.Vaccine · 2018Pooled it
- Controlled temperature chain for vaccination in low- and middle-income countries: a realist evidence synthesis.Bulletin of the World Health Organization · 2022Review
- Article
- 'Learn from the lessons and don't forget them': identifying transferable lessons for COVID-19 from meningitis A, yellow fever and Ebola virus disease vaccination campaigns.BMJ global health · 2021Review
- Strategies to Improve Coverage of Typhoid Conjugate Vaccine (TCV) Immunization Campaign in Karachi, Pakistan.Vaccines · 2020Article
- Mobilize to vaccinate: lessons learned from social mobilization for immunization in low and middle-income countries.Human vaccines & immunotherapeutics · 2020Article
- Health workers' perceptions and challenges in implementing meningococcal serogroup a conjugate vaccine in the routine childhood immunization schedule in Burkina Faso.BMC public health · 2020Article
- Evaluation of the Impact of Meningococcal Serogroup A Conjugate Vaccine Introduction on Second-Year-of-Life Vaccination Coverage in Burkina Faso.The Journal of infectious diseases · 2019Article
- Impact of serogroup A meningococcal conjugate vaccine for Africa.Human vaccines & immunotherapeutics · 2018Article
- Successful African introduction of a new Group A meningococcal conjugate vaccine: Future challenges and next steps.Human vaccines & immunotherapeutics · 2018Article
- Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015Review
- Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015Review
- Ambiguous Capture: Collaborative Capitalism and the Meningitis Vaccine Project.Medical anthropologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundA new group A meningococcal conjugate vaccine was developed to eliminate deadly meningitis epidemics in sub-Saharan Africa.
methodsFrom the outset of the project, advocacy and communication strategies were developed and adjusted as the project evolved in Europe, Africa, India, and the United States. Communications efforts were evidence-based, and involved partnerships with the media and various stakeholders including African ministries of health, the World Health Organization, UNICEF, Gavi, the Centers for Disease Control and Prevention, and Médecins Sans Frontières.
resultsThe implementation of an integrated communication strategy ensured the active cooperation of stakeholders while providing an organized and defined format for the dissemination of project-related developmental activities and the successful introduction of the vaccine.
conclusionsEarly in the project, a communications strategy that engaged stakeholders and potential supporters was developed. The strategy was implemented and adapted as the project matured. Linked communication proved to be key to the successful wide-scale introduction of the PsA-TT (MenAfriVac) vaccine in Africa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.